Bergen, Norway, April 23, 2025 – Cytovation ASA, a clinical stage oncology company focused on the development of its first-in-class bifunctional peptide CY-101, announces that it has raised NOK62 ...

More information: Yi-Wei Tsai et al, N-Cadherin promotes cardiac regeneration by potentiating pro-mitotic β-Catenin signaling ...

The lead drug emerging from the biotech's Helicon platform is billed as a "first-and-only-in-class" direct TCF-blocking beta-catenin inhibitor, which FogPharma says has potential as a treatment ...